Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1KEYNOTE-119 (all population), 20191OlympiAD, 2017olaparib vs. pembrolizumab alone 0.93 [0.65; 1.32]0.93 [0.65;1.32]olaparib vs. pembrolizumab alone 0.93 [0.65; 1.32]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]0.90 [0.66;1.23]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]pembrolizumab alone vs. olaparib 1.08 [0.76; 1.54]1.08 [0.76;1.54]pembrolizumab alone vs. olaparib 1.08 [0.76; 1.54]pembrolizumab alone vs. Standard of Care (SoC) 0.97 [0.82; 1.15]0.97 [0.82;1.15]pembrolizumab alone vs. Standard of Care (SoC) 0.97 [0.82; 1.15]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]1.11 [0.81;1.52]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]Standard of Care (SoC) vs. pembrolizumab alone 1.03 [0.87; 1.22]1.03 [0.87;1.22]Standard of Care (SoC) vs. pembrolizumab alone 1.03 [0.87; 1.22]Standard of Care (SoC)pembrolizumab aloneolaparibdirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)pembrolizumab aloneolaparib
Standard of Care (SoC)---1.03
0.87; 1.22		1.11
0.81; 1.52
pembrolizumab alone0.97
0.82; 1.15		---1.08
0.76; 1.54
olaparib0.90
0.66; 1.23		0.93
0.65; 1.32		---

pathologies: 140 - treatments: 483 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons